DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

Information source: MediQuest Therapeutics
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Raynaud's Disease; Raynaud's Disease Secondary to Scleroderma; Raynaud's Disease Secondary to Other Autoimmune Disease

Intervention: Nitroglycerin (Drug); Topical AmphiMatrix (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: MediQuest Therapeutics

Official(s) and/or principal investigator(s):
Jan Ohrstrom, PhD, Study Director, Affiliation: MediQuest Therapeutics


The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.

Clinical Details

Official title: A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Reduction in Raynaud's Condition Score

Secondary outcome: Frequency and severity of adverse events.

Detailed description: The purpose of this clinical study is to determine, in a controlled fashion, the ability of a topical formulation of Nitroglycerin, MQX-503, to improve the patient's health assessment as indicated by patient and physician assessments, decrease the frequency of Raynaud's events, decrease the duration of Raynaud's events, and decrease the symptoms (pain, tingling, numbness) in the fingers of Raynaud's patients. The study will include patients with moderate to severe primary Raynaud's Phenomenon (RP) and with moderate to severe Raynaud's Phenomenon secondary to autoimmune diseases, such as scleroderma.


Minimum age: 15 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- Outpatients ages 15 - 70.

- Patients with a diagnosis of Raynaud's phenomenon.

- Patients who agree to apply study medication to their fingers.

- Patients who are willing to stop current topical vasodilator therapies.

- Patients who agree not to start or change dosage of current oral vasodilator


- Patients who agree not to use any nitrate therapy while participating in this study.

- Negative pregnancy test in fertile women and agreement to use effective contraception

throughout the study. Exclusion Criteria:

- Patients who currently use nitrate medication or medications known to interact with


- Patients who have an allergy to nitroglycerin or common topical gel ingredients.

- Patients with a history of severe headaches.

- Patients with an unstable medical problem.

- Patients with cognitive or language difficulties that would impair their ability to

complete assessment of pain instruments.

- Patients who have had a recent heart attack or other uncontrolled heart condition.

- Patients who have participated in an investigational drug study within four weeks of

visit one.

- Patients who have clinically significant abnormal lab values.

- Patients who have had recent major abdominal, thoracic or vascular surgery.

- Patients with interfering skin conditions.

- Pregnant or nursing women or women unwilling to comply with contraceptive


Locations and Contacts

Stanford University, Stanford, California 94305, United States

University of Colorado Health Sciences Center, Denver, Colorado 80045, United States

University of Connecticut, Farmington, Connecticut 06030, United States

Georgetown University, Washington, District of Columbia 20007, United States

University of Chicago, Chicago, Illinois 60637, United States

Johns Hopkins University, Baltimore, Maryland 21224, United States

Boston University, Boston, Massachusetts 02118, United States

Arthritis Education and Treatment Center, PLLC, Grand Rapids, Michigan 49546, United States

University of Minnesota, Minneapolis, Minnesota 55455, United States

University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08093, United States

The Center for Rheumatology, Albany, New York 12206, United States

SUNY Stony Brook, Stony Brook, New York 11794, United States

Carolina Arthritis, Wilmington, North Carolina 28401, United States

University of Toledo, Toledo, Ohio 43614, United States

Medical University of South Carolina, Charleston, South Carolina 29425, United States

University of Texas at Houston, Houston, Texas 77030, United States

Medical College of Wisconsin, Milwaukee, Wisconsin 53226, United States

Additional Information

Sponsor web site

Starting date: December 2007
Last updated: February 3, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017